X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims for the development and regulatory approval of Foundation Medicine’s FoundationOne®CDx and FoundationOne®Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AnHeart Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.
Lead Product(s): Capivasertib,Fulvestrant
Therapeutic Area: Oncology Product Name: Truqap
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.
Lead Product(s): Encorafenib,Cetuximab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
The Partnership will focus on developing FoundationOne®CDx as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828, an investigational, oral, small molecule MDM2-p53 antagonist.
Lead Product(s): BI 907828
Therapeutic Area: Oncology Product Name: BI 907828
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2023
Details:
Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Lead Product(s): Bavdegalutamide
Therapeutic Area: Oncology Product Name: ARV-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Arvinas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2022
Details:
Partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi’s PRECISION 1 clinical trial for ABI-009. The goals are to increase patient match rate, reduce screen failure rate and increase speed of enrollment.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: ABI-009
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Aadi Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 09, 2022
Details:
TABRECTA® is the first therapy approved by the FDA for adult patients with metastatic NSCLC whose tumors have an alteration that leads to METex14.
Lead Product(s): Capmatinib Hydrochloride
Therapeutic Area: Oncology Product Name: Tabrecta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2021
Details:
FoundationOne®CDx to be used as a companion diagnostic for ALUNBRIG® (brigatinib), which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Lead Product(s): Brigatinib
Therapeutic Area: Oncology Product Name: Alunbrig
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
